You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cytarabine

Showing 1 - 25 of 1,522
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial in Tianjin ((cytarabine: daunorubicin) liposome for injection, Vyxeos)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (cytarabine: daunorubicin) liposome for injection
  • Vyxeos
  • Tianjin, China
    Institute of Hematology and Hospital of Blood Disease, Chinese A
Mar 24, 2023

Acute Myeloid Leukemia, Adult Trial in Hangzhou (cladribine + homoharringtonine + cytarabine)

Recruiting
  • Acute Myeloid Leukemia, Adult
  • cladribine + homoharringtonine + cytarabine
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Jun 13, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia Trial in Chapel

Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Biospecimen Collection
  • +3 more
  • Baltimore, Maryland
  • +2 more
Jan 19, 2023

Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Sep 18, 2023

Acute Myeloid Leukemia Trial in Suzhou (Venetoclax, Homoharringtonine, Cytarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Suzhou, Jiangsu, China
    Qiu Huiying
Mar 28, 2023

Autologous Stem Cell Transplantation, Conditioning Trial in Xi'an (modified BEAM, BEAM)

Not yet recruiting
  • Autologous Stem Cell Transplantation
  • Conditioning
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
Apr 14, 2023

Acute Myeloid Leukemia, MDS Trial (Cladribine, Cytarabine, Decitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Mar 1, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Tumor, Acute Myeloid

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • (no location specified)
Nov 15, 2022

Acute Myeloid Leukemia, Core-Binding Factor Trial in Shanghai (Fludarabine, Cytarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Core-Binding Factor
  • Shanghai, Shanghai, China
    Xianmin Song
May 5, 2022

Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult, Acute Lymphoblastic Leukemia, Adult Trial in Zhuhai (Thiotepa,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
  • Zhuhai, Guangdong, China
    The Fifth Affiliated Hospital of Sun Yat-sen University
Sep 25, 2023

Langerhans Cell Histiocytosis Trial in Shanghai (Prednisone+Cytarabine+vincristine,

Recruiting
  • Langerhans Cell Histiocytosis
  • Shanghai, China
    Shanghai Children's Medical Center
Jul 23, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Leukemia, Acute Myeloid Leukemia, AML Trial in Tampa (Selinexor, Daunorubicin, Cytarabine)

Completed
  • Leukemia
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Sep 30, 2022

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising

Not yet recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • (no location specified)
Nov 8, 2022

Acute Lymphoblastic Leukemia Trial in Suzhou (Cladribine, Fludarabine)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Oct 12, 2022

Acute Myeloid Leukemia Trial in Suzhou (Venetoclax Oral Tablet, Daunorubicin)

Recruiting
  • Acute Myeloid Leukemia
  • Suzhou, Jiangsu, China
  • +1 more
Jul 3, 2023

Adult Patients With Adverse Risk Acute Myeloblastic Leukemia Trial (Darzalex)

Not yet recruiting
  • Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
  • (no location specified)
Feb 27, 2023

Leukemia, Myeloid, Acute Trial in Poznan (Liposomal Annamycin, Cytarabine)

Recruiting
  • Leukemia, Myeloid, Acute
  • Liposomal Annamycin
  • Cytarabine
  • Bologna, Italy
  • +4 more
Jan 31, 2023

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease Trial (Venetoclax, Decitabine,

Not yet recruiting
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Venetoclax, Decitabine, Azacytidine, Cytarabine
  • (no location specified)
May 4, 2022

Lymphoblastic Leukemia in Children Trial (induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal

Not yet recruiting
  • Lymphoblastic Leukemia in Children
  • induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
  • +7 more
  • (no location specified)
Oct 24, 2023

Hematological Malignancy Trial in Ningbo (Etoposide, Cytarabine, PEG-rhG-CSF)

Recruiting
  • Hematological Malignancy
  • Ningbo, Zhejiang, China
    The Affiliated People's Hospital of Ningbo University.
Aug 18, 2022

Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 20, 2023

Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +4 more
  • Utrecht, Netherlands
    Princess Máxima Center for Pediatric Oncology
Feb 16, 2023

Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)

Recruiting
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 23, 2022

Leukemia, Myeloid, Acute Trial (Cytarabine, Venetoclax, CPX-351)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • Cytarabine
  • +3 more
  • (no location specified)
Nov 25, 2022